Pacira names senior VP, strategy
This article was originally published in Scrip
Parsippany, New Jersey-based Pacira Pharmaceuticals has named Dr Scott Braunstein to the newly created position of senior vice-president of strategy and corporate development. Dr Braunstein brings over 20 years of knowledge and experience from his time both as a practising physician and investor, as well as expertise from numerous commercial, consulting and operational roles advising on strategy and organizational objectives for biotechnology and pharmaceutical companies. He will be responsible for evaluating, integrating and optimizing the company's strategic opportunities for the lead commercial product Exparel (bupivacaine liposome injectable suspension); the company's hospital-based sales franchise; the DepoFoam-based internal pipeline product candidates; and external in-licensing and acquisition product candidates. Before joining Pacira, Dr Braunstein was at Everpoint Asset Management.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.